재발된 자궁경부암 환자의 한의 기반 통합 암 치료에 대한 증례보고
A Case Report of Traditional Korean Medicine-Based Integrative Oncology of Recurrent Cervical Cancer
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: To show a decrease in tumor recurrence and improvement in quality of life in patients with recurrent cervical cancer. Method: A 58-year-old female patient diagnosed with recurrent cervical cancer in February 2021 was treated for 14 months with integrative cancer treatment (ICT) to decrease the tumor size and improve chemotherapy-induced peripheral neuropathy (CIPN) and nausea. The patient underwent chemotherapy or concomitant chemoradiation therapy (CCRT) with ICT. Radiologic outcomes were assessed by abdomen & pelvis computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET-CT) based on the Response Evaluation Criteria in Solid Tumors (RECIST) protocol. Clinical outcomes were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), Eastern Cooperative Oncology Group (ECOG), and a numeric rating scale (NRS). Result: During the 14 months of treatment, the size and metabolic activity of the recurrent tumor decreased and underwent partial remission based on RECIST. The NRS scores for CIPN and nausea were improved, and the ECOG score improved from grade 2 to 1. No serious side effects of grade 3 or higher were noted on the NCI-CTCAE test. Conclusion: This case suggests that ICT may have a synergetic effect with chemotherapy or radiotherapy for recurrent cervical cancer.
Abstract
Objective: To show a decrease in tumor recurrence and improvement in quality of life in patients with recurrent cervical cancer. Method: A 58-year-old female patient diagnosed with recurrent cervical cancer in February 2021 was treated for 14 months with integrative cancer treatment (ICT) to decrease the tumor size and improve chemotherapy-induced peripheral neuropathy (CIPN) and nausea. The patient underwent chemotherapy or concomitant chemoradiation therapy (CCRT) with ICT. Radiologic outcomes were assessed by abdomen & pelvis computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET-CT) based on the Response Evaluation Criteria in Solid Tumors (RECIST) protocol. Clinical outcomes were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), Eastern Cooperative Oncology Group (ECOG), and a numeric rating scale (NRS). Result: During the 14 months of treatment, the size and metabolic activity of the recurrent tumor decreased and underwent partial remission based on RECIST. The NRS scores for CIPN and nausea were improved, and the ECOG score improved from grade 2 to 1. No serious side effects of grade 3 or higher were noted on the NCI-CTCAE test. Conclusion: This case suggests that ICT may have a synergetic effect with chemotherapy or radiotherapy for recurrent cervical cancer.
참고문헌 (19)
- National Cancer Center. Annual report of cancer statistics in Kroea in 2019, "Ministry of Health and Welfare", Ministry of Health and Welfare, 1~52 (2019)
- National Comprehensive Cancer Network, "Cervical Cancer", 1~90 (2022)
- Tewari KS, "Improved Survival with Bevacizumab in Advanced Cervical Cancer", N Engl J Med, 370(8), pp.734~743 (2014)
- Hsiao YH, "The Potential of Chinese Herbal Medicines in the Treatment of Cervical Cancer", Integr Cancer Ther, 18, pp.1534735419861693~ (2019)
- 오승윤, "Efficacy of Herbal Medicine as an Adjunctive Therapy of Chemotherapy for Cervical Cancer: A Systematic Review and Meta-analysis", 동의생리병리학회지, 34(5), pp.255~262 (2020), 한의병리학회[DOI]
- Campos LS, "Survival after Laparoscopic versus Abdominal Radical Hysterectomy in Early Cervical Cancer : A Randomized Controlled Trial", Asian Pac J Cancer Prev, 22(1), pp.93~97 (2021)
- Kim SI, "Comparison of abdominal and minimally invasive radical hysterectomy in patients with early stage cervical cancer", Int J Med Sci, 18(5), pp.1312~1317 (2021)
- Foucher T, "Recurrence Pattern of Cervical Cancer Based on the Platinum Sensitivity Concept : A Multi-Institutional Study from the FRANCOGYN Group", J Clin Med, 9(11), pp.3646~ (2020)
- Tewari KS, "Bevacizumab for advanced cervical cancer : final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial(Gynecologic Oncology Group 240)", The Lancet, 390(10103), pp.1654~1663 (2017)
- 이남헌, "항암단으로 치료한 암환자 100례의 혈청 VFGF, bEGF 및 platelet 수치 변화", 대한한방내과학회지, 26(4), pp.753~760 (2005), 대한한방내과학회
- Choi WC, "Rhus verniciflua Stokes against Advanced Cancer : A Perspective from the Korean Integrative Cancer Center", J Biomed Biotechonol, 2012, pp.874276~ (2012)
- Schoen-Angerer T, "High-Dose Viscum album Extract Treatment in the Prevention of Recurrent Bladder Cancer : A Retrospective Case series", PermJ, 19(4), pp.76~83 (2015)
- Majeed M, "Mistletoe lectins : From interconnecting proteins to potential tumour inhibiting agents", Phytomedicine Plus, 1(3), pp.100039~ (2021)
- Grossarth-Maricek R, "Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation(Iscador)", Eur J Med Res, 13(3), pp.107~120 (2008)
- Son MK, "SB365, Pulsatilla saponin D suppresses proliferation and induces apoptosis of pancreatic cancer cells", Oncol Rep, 30(2), pp.801~808 (2013)
- Hong SW, "SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities", Carcinogenesis, 34(9), pp.2156~2169 (2013)
- StaffNP, "Chemotherapy-Induced Peripheral Neuropathy : A Current Review", Ann Neurol, 81(6), pp.772~781 (2017)
- Hu LY, "Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy : Therapies Based on CIPN Mechanisms", Curr Neuropharmacol, 17(2), pp.184~196 (2019)
- 김은혜, "항암화학요법 유발 말초신경병증에 대한 침치료의 효과 : 체계적 문헌고찰 및 메타 분석", 대한한방내과학회지, 41(3), pp.350~361 (2020), 대한한방내과학회[DOI]